Tempus AI IPO
Tempus AI is a precision medicine company that uses artificial intelligence and data analytics to help physicians make more informed treatment decisions, particularly in oncology. The company builds and operates a platform that analyzes clinical and molecular data to provide personalized therapy recommendations. Investors are interested in its potential to transform cancer care through AI-driven insights and its growing database of genomic and clinical information.
What We Know
Tempus AI completed its initial public offering in June 2024, trading on NASDAQ under the ticker symbol "TEM." The company raised approximately $411 million in its IPO, pricing shares at $37 each. The offering was notable as one of the significant healthcare AI IPOs of 2024, reflecting continued investor interest in AI-powered healthcare solutions. As a newly public company, Tempus is focused on scaling its precision medicine platform and expanding its partnerships with healthcare providers and pharmaceutical companies. The company continues to build its proprietary dataset while working to demonstrate the clinical and economic value of its AI-driven approach to personalized medicine.
Frequently Asked Questions
Has Tempus AI had an IPO?
Yes, Tempus AI completed its IPO in June 2024 and is now publicly traded. The company trades on NASDAQ under the ticker symbol "TEM."
When is the Tempus AI IPO date?
Tempus AI already completed its IPO in June 2024, so there is no upcoming public offering. The company recently became publicly traded.
How can I buy Tempus AI stock?
You can buy Tempus AI stock through any brokerage account as it trades on NASDAQ under ticker "TEM." The stock has been available for public trading since June 2024.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts